Joydeep Banerjee

Joydeep Banerjee is the Executive Director and Program Lead for Individualized Neoantigen Therapy at Moderna, a position held since 2023. Prior to this role, they served in various leadership positions at 2seventy bio and bluebird bio, overseeing critical programs in oncology and corporate strategy. Joydeep previously completed a Ph.D. in Immunobiology at Yale University and a B.A. in Biochemistry at Columbia University. Earlier in their career, they gained experience through internships at Merck and DeciBio, and worked as a consultant and researcher in various settings.